Related Experiment Video
Updated: Oct 13, 2026

Reduced Itraconazole Concentration and Durations Are Successful in Treating Batrachochytrium dendrobatidis Infection in Amphibians
Published on: March 14, 2014
Oral terbinafine in tinea capitis in children
E Gruseck1, V Splanemann, O Bleck
1Department of Dermatology, University Clinics Eppendorf, Hamburg, Germany.
Insights
Terbinafine effectively treats tinea capitis in children, achieving complete remission with good tolerability. This antifungal medication offers a promising alternative to griseofulvin, though further studies are needed.
Area of Science:
- Dermatology
- Mycology
- Pediatrics
Background:
- Tinea capitis is a common pediatric fungal infection requiring systemic treatment.
- Griseofulvin is the standard treatment but necessitates prolonged therapy (months).
Purpose of the Study:
- To evaluate the efficacy and tolerability of terbinafine for treating tinea capitis in children.
- To compare in vitro activity of terbinafine and griseofulvin against dermatophytes.
Main Methods:
- Four pediatric patients (3-9 years) with culture-proven tinea capitis received terbinafine (125 mg/day) for 4-10 weeks.
- Minimal inhibitory concentration (MIC) testing was performed for terbinafine and griseofulvin against patient isolates.
Main Results:
- All four patients achieved complete clinical remission with terbinafine.
- Follow-up cultures were negative, indicating successful eradication.
- Terbinafine was well-tolerated in all cases.
- In vitro testing confirmed terbinafine's potent activity against dermatophytes.
Conclusions:
- Terbinafine demonstrates high efficacy and good tolerability for pediatric tinea capitis treatment.
- Further controlled trials are essential to establish optimal dosing, duration, and safety profiles for terbinafine.
Abstract:
Tinea capitis is a disease that frequently affects children. In most cases systemic antimycotic treatment is necessary Griseofulvin is still the drug of choice, but requires prolonged periods of treatment (several months). To estimate the efficiency and tolerability of terbinafine for treatment of tinea capitis in children, four patients (aged 3-9 years) with tinea capitis proven by culture were treated with terbinafine at a dose of 125 mg a day for different periods (4-10 weeks). Isolates were subjected to minimal inhibitory concentration testing against terbinafine and griseofulvin. In all four cases terbinafine treatment resulted in complete remission. The clinical response was accompanied by negative culture results on follow-up. Terbinafine was well tolerated in each case. Determination of the minimal inhibitory concentration confirmed the excellent in vitro activity of terbinafine against dermatophytes. Controlled studies involving a larger number of children are necessary to answer questions concerning dose and duration of terbinafine treatment as well as the frequency and severity of drug-related side-effects.
Related Concept Videos
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
The Skin Microbiota
Acne Infection
Cryptococcal Meningitis
Candidiasis
Antifungal Agents

